Sodium-glucose co-transporter 2 (SGLT2) inhibitors, an established therapeutic class for the management of type 2 diabetes, symptomatic heart failure and proteinuric kidney disease, primarily target the SGLT2 co-transporter found in the proximal tubule of the kidney1. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.